Sicherheit und Wirksamkeit des ENTERPRISE 2-Geräts bei der endovaskulären Behandlung von intrakraniellen Aneurysmen (EMPOWER)
ENTERPRISE 2 Register für Gefäßrekonstruktionsgeräte und Verabreichungssysteme: Eine multizentrische, prospektive, einarmige Beobachtungsstudie zur Bewertung der Sicherheit und Wirksamkeit des Geräts zur Erleichterung der endovaskulären Coil-Embolisation von intrakraniellen Aneurysmen
The study is designed to evaluate the safety and effectiveness of ENTERPRISE 2 vascular reconstruction device and delivery system (hereinafter referred to as ENTERPRISE 2) to facilitate endovascular coil embolization of intracranial aneurysms.
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Detaillierte Beschreibung
This is a prospective, multicenter, single-arm observational study, in which enrolled patients will be implanted with the ENTERPRISE 2 for evaluation of safety and effectiveness of ENTERPRISE 2 in real-world applications.
The study population will consist of 164 patients with ruptured or unruptured intracranial aneurysms and a parent vessel diameter of ≥2.5 mm and ≤4 mm. All patients will be implanted with the study device.
The enrolled patients will be followed at 30 days, 180 days, 1 year, 2 years, 3 years, 4 years and 5 years post procedure.
The primary endpoint is the incidence of aneurysm recanalization (at 180 days) evaluated through digital subtraction angiography (DSA). Secondary effectiveness endpoints include incidence of aneurysm recanalization (at 1 year), successful stent/coil placement rate (immediately post procedure), aneurysm occlusion (immediately post procedure, at 180 days and 1 year), incidence of retreatment (at 30 and 180 days, and 1, 2, 3, 4 and 5 years). Safety evaluation include: incidence of disabling stroke or neurological death (at 180 days and 1 year), incidence of in-stent thrombosis (at 180 days and 1 year), and incidence of in-stent stenosis (at 180 days and 1 year). Exploratory endpoints include stent wall apposition performance (intra-procedure), first-time deployment success rate (intra-procedure) and duration of stent deployment (intra-procedure).
Studientyp
Studientyp
Einschreibung (Tatsächlich)
Einschreibung
Kontakte und Standorte
Studienorte
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, China, 100070
- Beijing Tiantan Hospital, Capital Medical University
-
Beijing, Beijing Municipality, China, 100029
- Beijing Anzhen Hospital, Capital Medical University
-
-
Guangdong
-
Guangzhou, Guangdong, China
- Zhujiang Hospital of Southern Medical University
-
-
Henan
-
Zhengzhou, Henan, China, 450052
- The first affiliated hospital of Zhengzhou university
-
-
Hubei
-
Wuhan, Hubei, China, 430022
- Union Hospital, Tongji Medical College, Huazhong University of Science & Technology
-
-
Jiangsu
-
Nanjing, Jiangsu, China, 210008
- Nanjing Drum Tower Hospital
-
-
Jiangxi
-
Nanchang, Jiangxi, China, 330006
- The first affiliated hospital of Nanchang university
-
-
Liaoning
-
Shenyang, Liaoning, China, 110004
- Shengjing Hospital of China Medical University
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, China
- Huashan Hospital Shanghai Medical college, Fudan University
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310007
- Zhejiang Hospital
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Probenahmeverfahren
Studienpopulation
This study will be conducted in patients with unruptured or ruptured intracranial aneurysm with a parent vessel diameter of ≥2.5 mm and ≤4 mm.
Beschreibung
Inclusion Criteria:
- Patient (or his/her legal representative) understands the nature of the procedure and provides voluntary written informed consent for the use of his/her peri-procedural and follow-up data;
- Aged between 18 years and 80 years of age the time of consent;
- Patient has been diagnosed with ruptured (Hunt-Hess Grade I-III) or unruptured intracranial aneurysm and requires the endovascular treatment;
- Parent vessel with a diameter of ≥2.5 mm and ≤4 mm;
- Patient is willing to return to the investigational site for the post-procedure follow-up evaluations.
Exclusion Criteria:
- Severe co-morbidity associated with a life-expectancy of less than twelve months as determined by the investigator;
- Poor clinical condition with modified Rankin Scale (mRS) score ≥4;
- Having prior or potential severe allergic reaction to contrast medium;
- Known allergies to any of the device components, including Enterprise 2 and PROWLER® SELECT™ Plus Infusion Catheter;
- Angiogram demonstrating that the aneurysm is not appropriate for endovascular treatment (i.e. severe intracranial vessel tortuosity, stenosis, intracranial vasospasm not responsive to medical therapy);
- Arteriovenous malformation (AVM) in the territory of the target aneurysm;
- Unsuitable for the antithrombotic and/or anticoagulant therapies;
- Implantation of an intracranial stent associated with aneurysm or symptom distribution within 12 weeks prior to signature of Informed Consent Form;
- Implantation of a carotid stent associated with aneurysm or symptom distribution within 12 weeks prior to signature of Informed Consent Form;
- Evidence of active infection;
- Pregnant or lactating women;
- Having participated in clinical studies of other investigational drugs or devices within 30 days prior to signature of Informed Consent Form, excluding epidemiological studies of observational nature or natural history or not involving intervention;
- Pre-planned staged procedure of target aneurysms.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Beobachtungsmodelle: COHORT
- Zeitperspektiven: PROSPECTIVE
Anzahl der Gruppen / Kohorten
Kohorten und Interventionen
Gruppe / KohorteGruppe / Kohorte |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
ENTERPRISE 2 group
The study population enrolled for this clinical study is "aneurysm patients who need stent-assisted coiling treatment", using ENTERPRISE 2 device. |
The ENTERPRISE 2 Vascular Reconstruction Device is intended for use with occlusive devices in the treatment of intracranial aneurysms. |
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Incidence of aneurysm recanalization
Zeitfenster: at 180 days post procedure
|
Incidence of aneurysm recanalization (at 180 days) = number of target aneurysm recanalization (at 180 days) ÷ total number of target aneurysms receiving follow-up × 100%. The results of aneurysm angiography at 180-day follow-up will be obtained through DSA, and the post-procedure immediate aneurysm recanalization shown in angiograms will be graded as per the Raymond-Roy Classification Scale. The Raymond-Roy Classification at each follow-up time point increased by ≥ one class relative to that immediately after the procedure is defined as recanalization (e.g., Class I immediately after the procedure, Class II at 180-day follow-up). |
at 180 days post procedure
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Incidence of aneurysm recanalization
Zeitfenster: at 1 year post procedure
|
Incidence of aneurysm recanalization (at 1 year) = number of target aneurysm recanalization (at 1 year) ÷ total number of target aneurysms receiving follow-up × 100%. The results of aneurysm angiography at 1 year follow-ups will be obtained through DSA or MRA or CTA. |
at 1 year post procedure
|
|
Successful stent/coil placement rate
Zeitfenster: immediately post procedure
|
Successful stent/coil placement rate = number of target aneurysms with successful stent/coil placement ÷ total number of target aneurysms× 100%. Successful stent/coil placement is defined as successful stent deployment and successful delivery and placement of the coil at the target aneurysm assessed immediately post procedure through angiography. |
immediately post procedure
|
|
Aneurysm occlusion
Zeitfenster: immediately post procedure, at 180 days and at 1 year post procedure
|
Aneurysm occlusion rate = number of target aneurysms with Raymond-Roy Class I or II aneurysm occlusion÷ total number of target aneurysms× 100%. The aneurysm occlusion will be assessed by classifying the post-procedure immediate aneurysm occlusion shown in angiograms based on the Raymond-Roy Classification. |
immediately post procedure, at 180 days and at 1 year post procedure
|
|
Incidence of retreatment
Zeitfenster: at 30 days, 180 days, 1 year, 2 years, 3 years, 4 years and 5 years post procedure
|
Incidence of retreatment = number of target aneurysms receiving retreatment during the follow-up ÷ total number of target aneurysms receiving follow-up ×100%. Retreatment refers to any intervention to the target aneurysm after completing first stent-assisted coil embolization for the target aneurysm. |
at 30 days, 180 days, 1 year, 2 years, 3 years, 4 years and 5 years post procedure
|
Andere Ergebnismessungen
Andere Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Incidence of disabling stroke or neurological death
Zeitfenster: at 180 days, at 1 year post procedure
|
Incidence of disabling stroke or neurological death = number of patients with disabling stroke or neurological death ÷ total number of patients receiving follow-up × 100%. Stroke is defined as rapidly developing clinical signs of focal (or global) disturbance of cerebral function lasting more than 24 hours with no apparent cause other than of vascular origin, including ischemic stroke or hemorrhagic stroke (i.e., intraparenchymal hemorrhage (IPH), SAH, subdural hemorrhage (SDH), epidural hemorrhage (EDH)). Disabling stroke is defined as mRS score ≥ 3 assessed at a minimum of 90 days (+/- 30 days) post-stroke event. Neurological death, also called brain death, refers to irreversible loss of the capacity for consciousness combined with the irreversible loss of all brainstem functions, including the capacity to breathe. |
at 180 days, at 1 year post procedure
|
|
Incidence of in-stent thrombosis
Zeitfenster: at 180 days, at 1 year post procedure
|
Incidence of in-stent thrombosis = number of target aneurysms with parent vessel (in-stent) thrombosis during follow-up ÷ total number of target aneurysms receiving follow-up ×100%. |
at 180 days, at 1 year post procedure
|
|
Incidence of in-stent stenosis
Zeitfenster: at 180 days, at 1 year post procedure
|
Incidence of in-stent stenosis = number of target aneurysms with parent vessel (in-stent) stenosis during follow-up ÷ total number of target aneurysms receiving follow-up ×100%. Mild, moderate, and severe in-stent stenosis is clinically defined as a stenosis of <33%, 33-67%, and ≥67%, respectively, comparing with non-stented parent vessel [43, 44]. In this study, moderate and severe in-stent stenoses (with a stenosis of ≥33%) of the parent vessel are defined as in-stent stenosis. |
at 180 days, at 1 year post procedure
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Mitarbeiter
Mitarbeiter
Ermittler
Ermittler
- Hauptermittler: Xinjian Yang, Professor, Beijing Tiantan Hospital
- Hauptermittler: Shiqing Mu, Professor, Beijing Tiantan Hospital
- Hauptermittler: Qingrong Zhang, Professor, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
- Hauptermittler: Yuxiang Gu, Professor, Huashan Hospital Shanghai Medical college, Fudan University
- Hauptermittler: Chuanzhi Duan, Professor, Southern Medical University, China
- Hauptermittler: Shu Wan, Professor, Zhejiang Hospital
- Hauptermittler: Bo Yu, Professor, Shengjing Hospital
- Hauptermittler: Yang Wang, Professor, The First Affiliated Hospital of Nanchang University
- Hauptermittler: Sheng Guan, Professor, The First Affiliated Hospital of Zhengzhou University
- Hauptermittler: Wohua Zhao, Professor, Union Hospital, Tongji Medical College, Huazhong University of Science & Technology
- Hauptermittler: Xinjian Yang, Professor, Beijing Anzhen Hospital
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Studienbeginn
Primärer Abschluss (Tatsächlich)
Primärer Abschluss
Studienabschluss (Tatsächlich)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- CNV_2018_02
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
Johnson & Johnson Medical Device Companies have an agreement with the Yale Open Data Access (YODA) Project to serve as the independent review panel for evaluation of requests for clinical study reports and participant level data from investigators and physicians for scientific research that will advance medical knowledge and public health. Requests for access to the study data can be submitted through the YODA Project site at http://yoda.yale.edu.
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Produkt, das in den USA hergestellt und aus den USA exportiert wird
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .